Cord Blood News Volume 4.26 | Jul 5 2012

Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-Free Approach
Researchers show that c-KIT+ human first-trimester amniotic fluid stem cells can be fully reprogrammed to pluripotency without ectopic factors, by culture on Matrigel in human embryonic stem cell medium supplemented with the histone deacetylase inhibitor valproic acid. [Mol Ther] Full Article | Press Release

Priming of Late Endothelial Progenitor Cells with Erythropoietin before Transplantation Requires the CD131 Receptor Subunit and Enhances Their Angiogenic Potential
The authors postulated that priming endothelial colony-forming cells (ECFC) by adding epoetin α in culture medium prior to experiments might increase their angiogenic properties. They also explored the role of the CD131 subunit in erythropoietin priming of ECFC. [J Thromb Haemost] Abstract

Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation
Patients received either a myeloablative or a reduced intensity double umbilical cord blood transplantation followed by parathyroid hormone (PTH) at 100 μg daily for 28 days. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery. [Biol Blood Marrow Transplant] Abstract

Fluid Shear Stress Induces Differentiation of Circulating Phenotype Endothelial Progenitor Cells
When floating-circulating phenotype endothelial progenitor cells (EPCs) derived from ex vivo expanded human cord blood were exposed to controlled levels of shear stress in a flow-loading device, the bioactivities of adhesion, migration, proliferation, anti-apoptosis, tube formation, and differentiated type of EPC colony formation increased. [Am J Physiol Cell Physiol] Abstract

The Effects of Two Mesenchymal Cell Populations on Hepatocytes and Lymphocytes
Scientists cocultured human umbilical cord perivascular cells, or bone marrow-mesenchymal stromal cells, with rat hepatocytes, or human peripheral blood mononuclear cells (PBMC), in order to identify their effects on hepatocyte functionality and phytohemagglutinin-stimulated PBMC proliferation. [Liver Transpl] Abstract

Whatever Their Differentiation Status, Human Progenitor Derived – Or Mature – Endothelial Cells Induce Osteoblastic Differentiation of Bone Marrow Stromal Cells
Researchers confirmed that endothelial cells (ECs) induce osteoblastic differentiation of mesenchymal stem cells in vitro. Moreover, human umbilical vein endothelial cells can be replaced by progenitor-derived ECs, the latter being of great interest in tissue engineering. [J Tissue Eng Regen Med] Abstract

Systematic Assessment in an Animal Model of the Angiogenic Potential of Different Human Cell Sources for Therapeutic Revascularization
CD34+ cells from mobilized peripheral blood or umbilical cord blood hematopoietic progenitor cells were the only cells to promote new vessel growth, but did not incorporate into vessels. Only endothelial outgrowth cells incorporated into vessels, but these did not promote vessel growth. [Stem Cell Res Ther]
Abstract | Full Article

Association of SIRT1 Expression with Shear Stress Induced Endothelial Progenitor Cell Differentiation
Human umbilical cord blood-derived endothelial progenitor cells (EPCs) were exposed to laminar shear stress of 15 dyn/cm² by parallel plate flow chamber system. Shear stress enhanced EPC differentiation toward endothelial cells while inhibiting differentiation to smooth muscle cells. [J Cell Biochem] Abstract

ThermoGenesis Announces Sale of CryoSeal^® Product Line to Asahi
ThermoGenesis Corp. said that Asahi Kasei Medical Co., Ltd., has exercised its option to purchase the Company’s CryoSeal Fibrin Sealant System wound care product line for $2 million in cash. [ThermoGenesis Corp.] Press Release

Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
On behalf of Saneron CCEL Therapeutics, Inc., President and COO, Nicole Kuzmin-Nichols expressed strong support for the Cryo-Cell International, Inc. current executive management in response to a proxy bid by a former Board member. [PR Newswire] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Chief Scientific Officer (SynGen Inc.)

Group Leaders, Principle Scientists – Stem Cell Clinical Product R&D (Shanghai Hengrui Pharmaceuticals Co., Ltd)

Stem Cell Therapy Scientist (Paramount Recruitment)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.